Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats motor fluctuations. Sold as Apokyn, Kynmobi, Onapgo. Every FDA application for this active ingredient: 3 branded and 1 generic.
As of Nov 15, 2026, FDA lists 4 applications for Apomorphine Hydrochloride (sold as Apokyn, Kynmobi, Onapgo), first approved Apr 20, 2004, with 2 new uses approved and 1 published complete response letter.
First approved: Apr 20, 2004
Applications: 4
New uses approved: 2
Complete response letters: 1
Medicare spending, 2025: $63.3M
Orphan exclusivity until: Feb 3, 2032
First approved in the EU: May 28, 2001
First approved in Japan: Mar 30, 2012
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
IxenseTakeda Europe R Centre Ltd. · May 28, 2001 · withdrawn
Approvals in Japan (PMDA)
First approved in Japan 95 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Apokyn, new ingredientA drug with a new active ingredient indicated for the treatment of "off" episodes associated with Parkinson's disease (when levodopa-containing products… · Kyowa Hakko Kirin Co., Ltd. · Mar 30, 2012
Clinical Trials
10 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Kynmobi (apomorphine)Human Factors (Hf), Clinical Pharmacology And Biopharmaceutics, Safety
Approved
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
